Leonard Zehr, Author at BioTuesdays

Feature

KA Imaging Reveal device a game changer in reinventing X-ray with dual energy

X-ray manufacturer, KA Imaging, is reinventing dual energy X-rays with its Reveal 35C device, which can produce three images from a single exposure, overcoming clinical and technical issues that exist with traditional X...

March 23, 2021

Feature

Petros Pharma looking to pursue OTC status for its Stendra erectile dysfunction therapy

Petros Pharmaceuticals (NASDAQ:PTPI) has set up a steering committee with the aim of applying to the FDA to make its prescription erectile dysfunction (ED) therapy, Stendra, available as an over-the-counter product in a...

March 16, 2021

Feature

Kezar Life Sciences harnessing master regulators of cellular functions to tackle disease

Kezar Life Sciences (NASDAQ:KZR) is advancing two drug development programs that have the potential to address a number of indications by harnessing different “master regulators” of cellular function: protein...

March 9, 2021

Feature

111’s next-gen S2B2C model is transforming China’s legacy healthcare system

Shanghai-based 111, Inc. (NASDAQ:YI) is helping pioneer the S2B2C model in China as it builds an innovative healthcare platform in the country.

March 2, 2021

Feature

Keith Sullivan discusses turnaround plan for Neuronetics

As the recently installed president and CEO of Neuronetics (NASDAQ:STIM), a commercial-stage medical device company focused on designing, developing and marketing products that improve the quality of life for patients...

February 23, 2021

Feature

Achieve Life Sciences in pivotal trial with cytisinicline for new smoking cessation and nicotine addiction treatment

Achieve Life Sciences (NASDAQ:ACHV) began a pivotal trial in the fourth quarter of 2020 to evaluate cytisinicline, which is derived from the seeds of the laburnum tree, as a potential new treatment for smoking cessation...

February 16, 2021

Feature

VistaGen readies Phase 3 trial of novel, fast-acting neuroactive nasal spray in social anxiety disorder

VistaGen Therapeutics (NASDAQ:VTGN) plans to begin a Phase 3 clinical trial in the second quarter with PH94B, a neuroactive nasal spray designed to provide rapid onset of action for the acute treatment of anxiety in...

February 9, 2021

Feature

ARSTAT developing portfolio of transformational products for women’s health

Closely-held ARSTAT Pharmaceuticals is advancing two patented Phase 3-ready assets: Nuvocept, the first and only oral contraceptive designed for overweight and obese women, and another contraceptive brand, Duacept, as a...

February 2, 2021

Feature

Lineage Cell Therapeutics readies milestone-rich 2021 in 3 clinical programs

Lineage Cell Therapeutics (NYSE American, TASE:LCTX) expects to report important milestones in its cell therapy clinical programs in dry AMD, cervical spinal cord injury and oncology in 2021, as well as improve its...

January 26, 2021

Feature

PDS Biotech to report preliminary data from 3 Phase 2 oncology trials in 2021

PDS Biotechnology (NASDAQ: PDSB) expects to report preliminary data in the first or second quarter of 2021 from a collaboration with the NCI, evaluating its lead oncology product, PDS0101, for the treatment of advanced...

January 19, 2021

Author - Leonard Zehr

KA Imaging Reveal device a game changer in reinventing X-ray with dual energy

Petros Pharma looking to pursue OTC status for its Stendra erectile dysfunction therapy

Kezar Life Sciences harnessing master regulators of cellular functions to tackle disease

111’s next-gen S2B2C model is transforming China’s legacy healthcare system

Keith Sullivan discusses turnaround plan for Neuronetics

Achieve Life Sciences in pivotal trial with cytisinicline for new smoking cessation and nicotine addiction treatment

VistaGen readies Phase 3 trial of novel, fast-acting neuroactive nasal spray in social anxiety disorder

ARSTAT developing portfolio of transformational products for women’s health

Lineage Cell Therapeutics readies milestone-rich 2021 in 3 clinical programs

PDS Biotech to report preliminary data from 3 Phase 2 oncology trials in 2021

General

More